Zealand Pharma’s Roche-partnered amylin analogue demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...
After its latest pipeline clear out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...
In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...
Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...
Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while ...
With colon cancer deaths rising among younger adults and millions of eligible Americans skipping their colonoscopies, ...
The back-and-forth between the FDA and gene therapy developer uniQure is getting messier, with an agency spokesperson now ...
Tenaya leverages “human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high-throughput in vitro ...
Science has added a whole lot more cash to the bank, bringing in an impressive $230 million in its latest raise. | Science ...
Daiichi Sankyo’s European division is teaming up with German medtech Gaia to sell the latter company’s cardiovascular digital ...
The FDA has put a partial clinical hold on PepGen’s phase 2 mus | The FDA has put a partial clinical hold on PepGen’s phase 2 ...
Roche is plugging 710 billion won (about $484 million) into South Korea’s biopharma industry, with the goal of attracting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results